Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
Table 2
Comparison of mouse immune-related protein antigen profiling in primary ZMTH3 and MTH52c tumors with or without GLV-1h68 at day 42 after virus infection (). Folds of enhancement (a) or suppression (b) of mouse protein expression after virus injection are shown.
(a) Protein expression level: upregulated (day 42 after virus infection).
Antigen
GLV-1h68/untreated ratio (MTH52c)
GLV-1h68/untreated ratio (ZMTH3)
Classification
Apo A1
7.56
1.21
Anti-inflammatory protein
IFN-gamma
4.00
1.8
Proinflammatory cytokine
IL-6
7.04
5.52
Proinflammatory cytokine
IL-11
6.59
1.6
Pleiotropic cytokine
IL-18
8.00
3.21
Proinflammatory cytokine
IP-10 (CXCL10)
29.47
11.21
Interferon-gamma-induced protein
MCP-1 (CCL2)
18.36
4,99
Proinflammatory cytokine
MCP-3 (CCL7)
13.26
2.36
Proinflammatory cytokine
MCP-5 (CCL12)
3.84
7.13
Proinflammatory cytokine
M-CSF (KC/GROα)
8.28
3.51
Proinflammatory cytokine
MDC (CCL22)
4.02
1.97
chemokine
MIP-1beta
9.34
1.66
Proinflammatory cytokine
MIP-2 (CXCL2)
6.91
11.93
Proinflammatory chemokine
MMP-9
12.68
26.31
Matrix Metalloproteinase-9
TIMP-1
5.05
2.91
Tissue inhibitor of metalloproteinase type-1
TNF-alpha
6.47
1.5
Proinflammatory cytokine
(b) Protein expression level: downregulated (day 42 after virus infection).
